Compare GSK plc (GSK) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Roundhill NVDA WeeklyPay ETF — how do they compare? GSK plc trades at $52.66 (market cap $101.34B), while Roundhill NVDA WeeklyPay ETF trades at $36.54. The key difference: GSK plc pays a 3.49% dividend while Roundhill NVDA WeeklyPay ETF pays none, and GSK plc is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| GSK | NVDW | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $53.42 |
52-Week Low | $36.20 | $31.88 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
NVDW trades at $36.39, down 3.12% today, with technical indicators showing mixed signals—a bullish overall trend but bearish moving averages. The stock faces resistance near $38 and support at $36. Recent corporate actions include multiple dividend payments in 2026, with Seeking Alpha highlighting its role as a quasi-synthetic leveraged play on Nvidia, offering a variable income stream.
The outlook hinges on Nvidia's performance, with potential for high yields but significant payout volatility. Risks include dependency on NVDA's stock movements and fluctuating dividends. Investors should weigh the income potential against the inherent volatility and leveraged structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
